Get Your Personalized Supplement StackSupplement Stack Quiz

Bifidobacterium Infantis Bi211

Also known as: *B. infantis*, *Bifidobacterium infantis Bi211*, *Bifidobacterium infantis*

Overview

*Bifidobacterium infantis* is a species of bacteria that is part of the healthy gut microbiome, predominantly found in infants. This probiotic strain is notable for its ability to ferment complex carbohydrates, specifically human milk oligosaccharides, which are critical for neonatal gut development. It is utilized primarily as a dietary supplement to support gut health and is beneficial for populations including preterm infants and individuals suffering from irritable bowel syndrome (IBS). Research has indicated that *B. infantis* can enhance gut health and potentially decrease rates of necrotizing enterocolitis (NEC) and late-onset sepsis (LOS) in preterm infants. The evidence supporting its use is moderate, with systematic reviews highlighting its efficacy in relevant clinical contexts.

Benefits

The primary benefits of *Bifidobacterium infantis* include: (1) Reducing the risk of NEC and LOS in preterm infants as substantiated by a meta-analysis showing a relative risk (RR) of 0.38 in supplemented infants; (2) Alleviating IBS symptoms such as abdominal pain and bloating, with composite probiotics improving overall symptom management according to systematic evidence. Other potential benefits are currently being explored, particularly concerning neurodegenerative diseases, but findings remain preliminary and largely animal-based. Populations that may benefit the most from *B. infantis* include preterm infants and adults with IBS, showcasing significant clinical outcomes in both cases.

How it works

*Bifidobacterium infantis* promotes gut health by modulating the gut microbiota composition and enhancing intestinal barrier function. It plays a role in the immune system, influencing the production of gut-derived metabolites and cytokines, which mediate inflammatory responses. As a probiotic, it colonizes the colon rather than being systemically absorbed, impacting gastrointestinal function directly through its actions within the gut.

Side effects

Overall, *Bifidobacterium infantis* is considered safe, with infrequent and mild side effects reported, such as bloating or gas. Rarely, there may be a risk of infections in immunocompromised individuals, though this is uncommon. There are no significant drug interactions associated with its use, but caution is advised for individuals who are severely immunocompromised. Given the safety profile, it is recommended to evaluate the specific health status of potential users, particularly vulnerable populations like preterm infants and those with weakened immune systems.

Dosage

Optimal dosages for *Bifidobacterium infantis* typically range from 10^8 to 10^9 CFU per serving, depending on the specific product formulation. While no minimum effective dose is firmly established, it is generally included in probiotic blends. It is recommended to take this supplement with food to enhance its survival through the gastrointestinal tract. Current guidelines do not specify maximum safe doses, as *B. infantis* is deemed safe at commonly used probiotic levels.

FAQs

How should I store *B. infantis* supplements?

These supplements should be stored in a cool, dry place to maintain their viability.

Is *B. infantis* safe for everyone?

While generally safe, it's advisable for immunocompromised individuals to consult a healthcare provider before use.

When is the best time to take *B. infantis*?

It's recommended to take *B. infantis* with meals to improve its gut survival rate.

How long until I see results with *B. infantis*?

Benefits can vary; some individuals may notice improvements after several weeks of consistent use.

Is *B. infantis* a cure for gut issues?

It is not a cure-all; the benefits are specific to strain and condition, and should be viewed as part of a broader treatment plan.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/37460707/ – This systematic review with meta-analysis focused on probiotics in preterm infants, demonstrating that those receiving *B. infantis* showed a significant reduction in NEC risk, compared to those without it. The high sample size (14,606 infants) provided strong evidence, though it noted limitations of indirect evidence requiring further RCTs.
https://pubmed.ncbi.nlm.nih.gov/28166427/ – This meta-analysis analyzed five studies involving IBS patients and found that composite probiotics with *B. infantis* are effective in alleviating IBS symptoms. While the quality was moderate due to limited studies on single-strain *B. infantis*, the results suggested clinical relevance in symptom management.
https://www.mdpi.com/2072-6643/17/3/391 – This systematic review examined various studies on the potential benefits of probiotics, highlighting emerging evidence that *B. infantis* may confer benefits in neurodegenerative diseases, although most data comes from animal models. More human-centric research is necessary to support these findings.
https://www.mdpi.com/2072-6643/16/20/3510 – The article provides insight into the effects of probiotics, emphasizing the interactions of specific strains like *B. infantis* with gut health. It supports the growing body of literature suggesting positive health outcomes, particularly in vulnerable populations such as preterm infants.